Deceased donor liver transplantation from donors with central nervous system malignancy: Experience of the Inonu University

İstanbul Kuzey Klinikleri

Cuneyt Kayaalp¹  Veysel Ersan¹  Fatih Ozdemir¹  Sezai Yilmaz¹  Bora Barut¹  Burak Isik¹  Cemalettin Koc¹  Volkan Ince¹ 

[1] Department of General Surgery, Inonu University, Liver Transplantation Institute, Malatya, Turkey;

关键词: central nervous system tumor;    deceased;    liver transplantation.;   

DOI  :  10.14744/nci.2017.74436

来源: DOAJ

【 摘 要 】

INTRODUCTION[|]Liver transplantation from deceased donors with a central nervous system (CNS) malignancy has some risk of tumor transmission to the recipient. Though the risk is small, this group of donors is regarded as marginal. The use of marginal grafts may be an acceptable alternative practice in order to expand the donor pool in countries where there is a shortage of donated organs. The aim of this study was to examine and present the outcomes of liver transplantations performed using donors with a CNS tumor.[¤]METHODS[|]Between March 2002 and July 2017, 1990 (deceased donor: n=399, 20%; living donor: n=1591, 80%) liver transplantations were performed at the center. Of the 399 deceased donors, 17 (4.2%) had a CNS tumor. The data of donors with a CNS tumor and of recipients who survived for more than 1 month (n=11) were retrospectively reviewed. Demographic data, the grade of the CNS tumor, tumor transmission to recipient data, and survival rates were analyzed.[¤]RESULTS[|]Only 2 (18%) grafts were provided locally, 6 (54%) were offered to the transplantation center after all of the national centers had declined them, and 3 (37%) were made available to us by the national coordination center for patients with a documented notification of urgency. High-grade (grade III-IV) brain tumors were detected in 7 (64%) donors, while low-grade (grade I-II) tumors were found in 2 patients. The remaining 2 donors were not pathologically graded because the diagnosis was made radiologically. The 1-, 3-, and 5-year overall and tumor-free survival of the patients was estimated at 100%, 70%, and 45%, respectively.[¤]DISCUSSION AND CONCLUSION[|]A median survival of 40 months (range: 13-62 months) was achieved in recipients of grafts from a donor with a CNS tumor and no donor-related malignant transformation was observed.[¤]

【 授权许可】

Unknown